CTLA4 and central nervous system cancer: With the anti-CTLA-4 and the anti-PD-1 treatment, all the “responsive” and “partially responsive” models demonstrated statistical decrease in the percentage of Ki67+ glioma cells in comparison with corresponding untreated controls (Figure 5).